George Washko
Pulmonary Disease · Boston, MANPI 1972594752
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,680 of the $101,353 with a category attached, or 67.8%. 9 manufacturers reported payments, led by Vertex at 34.8% of the total. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $1388.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$35K
- AstraZeneca$33K
- Astrazeneca UK Limited$15K
- Pulmonx Corporation$9K
- Actelion Pharmaceuticals US, Inc.$4K
- Polarean, Inc.$3K
- plus $2K from 3 others
Across 19 payments — averaging $25,880 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$442K
- United Therapeutics Corporation$44K
- Sanofi$6K
What the payments were for
- Consulting fees$68,68068%
- Speaking & faculty fees$9451%
- Travel & lodging$30,12030%
- Food & beverage$1,6072%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 15 | $35,243 |
| AstraZeneca | 25 | $32,966 |
| Astrazeneca UK Limited | 15 | $14,907 |
| Pulmonx Corporation | 3 | $8,650 |
| Actelion Pharmaceuticals US, Inc. | 3 | $4,185 |
| Polarean, Inc. | 1 | $3,000 |
| Janssen Research & Development, LLC | 4 | $1,200 |
| Boehringer Ingelheim | 4 | $1,031 |
| United Therapeutics Corporation | 3 | $171 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Pulmonx Endobronchial Valve EBV$7,950
- OPSUMIT$4,162
- UPTRAVI$4,162
- FASENRA$3,894
- TEZSPIRE$3,893
- XENOVIEW$3,000
- BREZTRI$2,919
- OFEV$945
- ZEPHYR ENDOBRONCHIAL VALVE$700
- PULMONX CHARTIS TABLET CONSOLE$700
- CHARTIS CATHETER$700
- ZEPHYR DELIVERY CATHETER$700
How this compares
$101,353 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- Aaron WaxmanBoston$88K
- Kelsey SackBoston$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.